Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 13/20 | 0.64 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1396866 | 1.00 | METAP2 (0.64) | METAP2FAAHADORA3ADORA2AADORA1 | |
| SCHEMBL2201560 | 0.92 | METAP2 (0.72) | METAP2FAAHADORA3ADORA2AADORA1 | |
| SCHEMBL2202320 | 0.92 | METAP2 (0.72) | METAP2FAAHADORA3ADORA2AADORA1 | |
| SCHEMBL2203237 | 0.92 | METAP2 (0.72) | METAP2FAAHADORA3ADORA2AADORA1 | |
| SCHEMBL2200840 | 0.89 | METAP2 (0.56) | METAP2ADORA3ADORA2AADORA1FFAR2 | |
| SCHEMBL2200845 | 0.89 | METAP2 (0.56) | METAP2ADORA3ADORA2AADORA1FFAR2 | |
| SCHEMBL2202518 | 0.85 | METAP2 (0.57) | METAP2 | |
| SCHEMBL2202512 | 0.85 | METAP2 (0.57) | METAP2 | |
| SCHEMBL2203182 | 0.84 | METAP2 (0.56) | METAP2ADORA3ADORA2AADORA1FFAR2 | |
| SCHEMBL2202569 | 0.84 | METAP2 (0.56) | METAP2ADORA3ADORA2AADORA1FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912994-B1 | ADENINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | claimed |
| US-7977343-B2 | Adenine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-07-12 | — | — | US | claimed |
| US-8846694-B2 | Pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | METAP2, METAP1, ENPEP | METAP2 1/4885FAAH 2378/4885ADORA3 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.